Sanofi Consumer Healthcare India Limited has announced its unaudited financial results for the quarter ended March 31, 2026, demonstrating strong operational performance across key metrics. The Board of Directors approved the results during a meeting held on April 28, 2026, from 1:00 p.m. to 3:40 p.m. The company has submitted the required financial documentation to both BSE Limited and National Stock Exchange of India Limited, complying with SEBI Listing Regulations.

Financial Performance Highlights

The company delivered impressive financial results for Q4FY26, with net profit reaching ₹678 million compared to ₹500 million in the corresponding quarter of the previous year, representing a 35.60% year-over-year growth. Revenue grew to ₹2,348 million from ₹1,778 million, reflecting strong business momentum of 35.29% growth.

Basic and diluted earnings per share (Rs. 10/- each) stood at ₹29.44 for Q4FY26, compared to ₹21.69 in the same quarter of the previous year. Total income from operations for the quarter ended March 31, 2026 was recorded at ₹2,348 million.

Sales Performance and Market Growth

The company reported sales of products worth ₹2,063 million for the quarter. Domestic sales demonstrated strong growth of 15.50% aided by successful product relaunches, while export sales surged by 144.40% on a lower base compared to the corresponding quarter of the previous year.

Product Portfolio Impact

The company had voluntarily recalled Depura Kids, Allegra Suspension and Combiflam Suspension in 2024 as a precautionary measure. Combiflam Suspension was successfully relaunched during the quarter ended June 2025, while Allegra Suspension and Depura Kids were relaunched in the quarter ended September 2025. These strategic relaunches contributed to the improved domestic sales performance.

Regulatory Compliance Updates

The company addressed the impact of New Labour Codes notified by the Government of India effective November 21, 2025. An incremental financial impact of ₹24 million was recognized as past service cost, resulting in increased gratuity liability and compensated absences due to changes in wage definitions under Employee Benefits Expense. The company does not have any subsidiary, associate or joint ventures as on March 31, 2026.

Newspaper Publication Compliance

Following regulatory requirements, the company published its Q4FY26 unaudited financial results in newspapers on April 29, 2026. The publication appeared in Business Standard and Sakal newspapers, fulfilling the mandatory disclosure obligations under SEBI regulations. The company formally intimated both BSE Limited and National Stock Exchange of India Limited about the newspaper publication through official correspondence dated April 30, 2026.

Sanofi Consumer Healthcare India Limited announced the resignation of its statutory auditor, Kalyaniwalla & Mistry LLP, effective April 30, 2026. The resignation stems from a disagreement over audit fees, marking an abrupt end to what was intended to be a five-year auditing relationship.

Auditor Resignation Details

Kalyaniwalla & Mistry LLP, Chartered Accountants (Firm Registration No.: 104607W / W100166), submitted their resignation letter on April 30, 2026, citing commercial viability concerns. The auditing firm had requested a fee increase for FY 2026 based on their estimated effort required for the audit, but the company declined to accommodate this request.

Background of the Fee Dispute

The auditing firm had initially been appointed for a five-year term covering financial years from January 01, 2024, to December 31, 2028, following approval at the annual general meeting held on April 25, 2024. In their resignation letter, Kalyaniwalla & Mistry LLP referenced their email dated April 25, 2026, requesting revision of statutory audit fees for FY 2026.

The company's response on April 29, 2026, expressed inability to accommodate the fee increase request. Following this rejection, the auditing firm reassessed their position based on Standards on Auditing and Standards on Quality Control issued by the Institute of Chartered Accountants of India.

Regulatory Compliance and Disclosures

Sanofi Consumer Healthcare India Limited has fulfilled its regulatory obligations by informing both BSE (Scrip Code: 544250) and NSE (Symbol: SANOFICONR) about the auditor resignation. The disclosure was made pursuant to Regulation 30 read with Schedule III of the SEBI Listing Regulations and SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026.

Auditor's Professional Assessment

In their resignation letter, Kalyaniwalla & Mistry LLP clarified that the resignation does not arise from any inability to obtain sufficient and appropriate audit evidence. The firm emphasized that there are no other circumstances connected with the resignation that should be brought to the attention of the Board of Directors, beyond the fee-related commercial considerations.

The auditing firm stated they would not be able to undertake the audit at fee levels lower than their proposed increase for FY 2026, considering their estimate of time and effort involved while maintaining professional standards. Partner Sai Venkata Ramana Damarla signed the resignation letter on behalf of the firm.

Documentation and Next Steps

The company has attached the complete resignation letter and required regulatory disclosures as annexures to their stock exchange filing. Company Secretary and Compliance Officer Nikunj Kumar Savaliya signed the regulatory disclosure, ensuring all mandatory information has been provided to stakeholders and regulatory authorities.